Kimberly E. Vanover, SVP, Clinical Development at Intra-Cellular Therapies, Inc. (ITCI), sold 9,375 shares at $15.26 ($143K) on 2016-12-15, disclosed to the SEC on 2016-12-19.
Scheduled sale ($143k) by SVP, Clinical Development under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $15.19 | 5,000 | $76K | 53.2% |
| 2 | $15.26 | 2,500 | $38K | 26.7% |
| 3 | $15.28 | 1,875 | $29K | 20.1% |
| Total | $15.23 avg | 9,375 | $143K | 100% |
| Filing → |
| ITCI | SELL | 2018-01-10 | $13K | — | Filing → |
| ITCI | SELL | 2018-01-05 | $21K | — | Filing → |
| ITCI | SELL | 2017-01-09 | $13K | — | Filing → |